Capricor Therapeutics (NASDAQ:CAPR) Shares Fall 64% Following Clinical Data Disclosure -- Investors with Losses Notified to Contact BFA Law before September 28 Deadline
Bleichmar Fonti & Auld LLP announced that a securities fraud class action has been filed against Capricor Therapeutics and certain senior executives in the U.S. District Court for the Southern District of California, captioned Nkamga v. Capricor Therapeutics, Inc. et al., with a September 28, 2026 lead plaintiff deadline.
Key figures
- Adcom vote
- non-binding 9-3 against efficacy
- Second drop pct
- 36%
- Close 2026 07 24
- 19.7
- Close 2026 07 27
- 7
- Close 2026 07 29
- 6.57
- Close 2026 07 30
- 4.19
- Largest stock drop pct
- 64.5%
- Lead plaintiff deadline
- September 28, 2026
- Second drop usd per share
- 2.38
- Largest stock drop usd per share
- 12.7
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.